Page 55 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

34 PART I The Biology and Pathogenesis of Cancer

352. Shelton GH, Grant CK, Cotter SM, et al.: Feline immunodefi- 372. Zeidner NS, Strobel JD, Perigo NA, et al.: Treatment of FeLV-
ciency virus and feline leukemia virus infections and their rela- induced immunodeficiency syndrome (FeLV-FAIDS) with con-
tionships to lymphoid malignancies in cats: a retrospective study trolled release capsular implantation of 2′,3′-dideoxycytidine,
VetBooks.ir 353. Hardy Jr WD, Zuckerman BE, MacEwen EG, et al.: A feline leu- 373. DeClerq E, Sakuma T, Baba M, et al.: Antiviral activity of phos-
Antiviral Res 11:147–160, 1989.
(1968-1988), J Acquir Immune Defic Syndr 3:623–630, 1990.
kemia and sarcoma virus–induced tumor-specific antigen, Nature
270:249–251, 1977. phonymethoxyalkyl derivatives of purines and pyrimidines, Antivi-
ral Res 8:261–272, 1987.
354. Hardy Jr WD, Zuckerman EE, Essex M, et al.: Feline oncornavi- 374. Hoover EA, Ebner JP, Zeidner NS, et al.: Early therapy of feline
rus–associated cell membrane antigen: anFeLV- and FeSV-induced leukemia virus infection (FeLV-FAIDS) with 9-(2-phosphonylme-
tumor-specific antigen. In Clarkson B, Marks PA, Till JE, editors: thoxyethyl) adenine (PMEA), Antiviral Res 16:77–92, 1991.
Differentiation of normal and neoplastic hematopoietic cells. Cold Spring 375. Hoover EA, Zeidner NS, Mullins JI: Therapy of presymptomat-
Harbor, New York, 1978, Cold Spring Harbor Laboratory Press. icFeLV-induced immunodeficiency syndrome with AZT in combi-
355. Francis DP, Cotter SM, Hardy Jr WD, et al.: Comparison of virus- nation with α-interferon, Ann NY Acad Sci 616:258–269, 1990.
positive and virus-negative cases of feline leukemia and lymphoma, 376. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al.: Alpha-
Cancer Res 39:3866–3870, 1979. Interferon (2b) in combination with zidovudine for the treatment
356. McClelland AJ, Hardy WD, Zuckerman EE: Prognosis of healthy of presymptomatic feline leukemia virus–induced immunodefi-
feline leukemia virus infected cats. In Hardy WD, Essex M, ciency syndrome, Antimicrob Agents Chemother 34:1749–1756,
McClelland AJ, editors: Feline leukemia virus, New York, 1980, 1990.
Elsevier/North-Holland, pp 121–126. 377. Zeidner NS, Mathiason-DuBard CK, Hoover EA: Reversal of
357. Cotter SM: Feline leukemia virus: pathophysiology, prevention and feline leukemia virus infection by adoptive transfer of lectin/inter-
treatment, Cancer Invest 10:173–181, 1992. leukin-2–activated lymphocytes, interferon-alpha and zidovudine,
358. Cotter SM: Management of healthy feline leukemia virus–positive J Immunother 14:22–32, 1993.
cats, J Am Vet Med Assoc 199:1470–1473, 1991. 378. Hardy Jr WD, McClelland AJ, Zuckerman EE, et al.: Prevention
359. August JR: Husbandry practices for cats infected with feline leu- of the contagious spread of feline leukaemia virus and the develop-
kemia virus or feline immunodeficiency virus, J Am Vet Med Assoc ment of leukaemia in pet cats, Nature 263:326–328, 1976.
199:1474–1477, 1991. 379. Legendre AM, Hawks DM, Sebring R: Comparison of the efficacy
360. Kociba GJ, Lange RD, Dunn CD, et al.: Serum erythropoietin of three commercial FeLV vaccines in a natural challenge, J Am Vet
changes in cats with feline leukemia virus–induced erythroid apla- Med Assoc 199:1456–1462, 1991.
sia, Vet Pathol 20:548–552, 1983. 380. Hendrick MJ, Kass PH, McGill LD, et al.: Postvaccinal sarcomas in
361. Snyder Jr HW, Singhal MC, Hardy Jr WD, et al.: Clearance of feline cats, J Natl Cancer Inst 86:341–343, 1994.
leukemia virus from persistently infected pet cats treated by extracor- 381. Macy DW: Unpublished data, 1994.
poreal immunoadsorption is correlated with an enhanced antibody 382. Varmus HE: Form and function of retroviral proviruses, Science
response to FeLV gp70, J Immunol 132:1538–1543, 1984. 216:812–820, 1982.
362. MacEwen EG: Current immunotherapeutic approaches in small ani- 383. Coffin JM: Structure, replication and recombination of retrovirus
mals, Columbus, OH, 1986, Proceedings of the KalKan Sympo- genomes: some unifying hypotheses, J Gen Virol 42:1–26, 1979.
sium on Oncology. 384. Besmer P: Acute transforming feline retroviruses, Contemp Top
363. Kitchen LW, Mather FJ: Hematologic effects of short-term oral Microbiol Immunol 107:1–27, 1993.
diethylcarbamazine treatment given to chronically feline leukemia 385. Essex M, Klein G, Synder SP, et al.: Antibody to feline oncornavi-
virus infected cats, Cancer Lett 45:183–187, 1989. rus–associated cell membrane antigen in neonatal cats, Int J Cancer
364. Kitchen LW, Cotter SM: Effect of diethylcarbamazine on serum 8:384–390, 1971.
antibody to feline oncornavirus–associated cell membrane antigen 386. Essex M, Cotter SM, Hardy Jr WD, et al.: Feline oncornavirus–
in feline leukemia virus cats, J Clin Lab Immunol 25:101–103, associated cell membrane antigen. IV. Antibody titers in cats with
1988. naturally occurring leukemia, lymphoma, and other diseases, J Natl
365. Barta O: Immunoadjuvant therapy. In Kirk RW, Bonagura JD, Cancer Inst 55:463–467, 1975.
editors: Kirk’s current veterinary therapy XI: small animal practice, 387. Patnaik AK, Liu SK, Hurvitz AI, et al.: Nonhematopoietic neo-
Philadelphia, 1992, WB Saunders, pp 217–223. plasms in cats, J Natl Cancer Inst 54:855–860, 1975.
366. Elmslie RE, Ogilvie GK, Dow SW, et al.: Evaluation of a biologic 388. Macy DW: Unpublished data, 1992.
response modifier derived from Serratia marcescens: effects on feline 389. Sieblink HJ, Chu I, Rimmelzwaan GF, et al.: Isolation and partial
macrophages and usefulness for the prevention and treatment of characterization of infectious molecular clones of feline immunodefi-
viremia in feline leukemia virus–infected cats, Mol Biother 3:231– ciency virus directly obtained from bone marrow DNA of a naturally
238, 1991. infected cat, Davis, CA, 1990, Paper presented at the First Interna-
367. Gasper PW, Fulton R, Thrall MA: Bone marrow transplantation: tional Conference of Feline Immunodeficiency Virus Researchers.
update and current considerations. In Kirk RW, Bonagura JD, edi- 390. Hoise MJ, Jarrett O: Serological responses of cats to feline immu-
tors: Kirk’s current veterinary therapy XI: small animal practice, Phila- nodeficiency virus, AIDS 4:215–220, 1990.
delphia, 1992, W.B. Saunders, pp 493–495. 391. Yamamoto JK, Sparger E, Ho EW, et al.: Pathogenesis of experi-
368. Tompkins MB, Cummins JM: Response of feline leukemia virus– mentally-induced feline immunodeficiency virus infection in cats,
induced nonregenerative anemia to oral administration of an inter- Am J Vet Res 49:1246–1258, 1988.
feron-containing preparation, Feline Pract 12:6–15, 1982. 392. Yamamoto JK, Hansen H, Ho EW, et al.: Epidemiologic and clini-
369. Tizard I: Use of immunomodulators as an aid to clinical manage- cal aspects of feline immunodeficiency virus infection in cats from
ment of feline leukemia virus–infected cats, J Am Vet Med Assoc the continental United States and Canada and possible mode of
199:1482–1485, 1991. transmission, J Am Vet Med Assoc 194:213–220, 1989.
370. Gingerich DA: Lymphocyte T-cell immunomodulator (LTCI): 393. North TW, North GLT, Pedersen NC: Feline immunodeficiency
review of the immunopharmacology of a new veterinary biologic, virus: a model for reverse transcriptase–targeted chemotherapy for
Intern J Applied Res Vet Med 6:61–68, 2008. acquired immune deficiency syndrome, Antimicrob Agents Che-
371. Polas PV, Swenson CL, Sams R, et al.: In vitro and in vivo evidence mother 33:915–919, 1989.
that the antiviral activity of 2-3-dideoxycytidine is target cell– 394. Fleming EJ, McCaw DL, Smith JA, et al.: Clinical hematologic and
dependent in a feline retrovirus animal model, Antimicrob Agents survival data from cats infected with feline immunodeficiency virus:
Chemother 34:1414–1421, 1990. 42 cases (1983-1988), J Am Vet Med Assoc 199:913–916, 1991.